SLXN Silexion Therapeutics Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2022416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-43.1%
TTM EPS YoY-211.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-266.0%
ROA-143.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets56.5%
Debt / equity0.00x
Current ratio1.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $7.14M | $5.82M | $3.71M |
| SG&A expense | $4.49M | $6.76M | $973,000 |
| Operating income | -$11.63M | -$12.57M | -$4.68M |
| Pretax income | -$11.91M | -$16.51M | -$5.08M |
| Income tax | $3,000 | $10,000 | $32,000 |
| Net income | -$11.91M | -$16.52M | -$5.11M |
| EBITDA | -$11.62M | -$12.55M | -$4.64M |
| EPS (basic) | 8.96 | 394.94 | 44.23 |
| EPS (diluted) | 8.96 | 394.94 | 44.23 |
| Weighted avg. shares (diluted) | 1.33M | 41,635 | 111,726 |
| Balance sheet | |||
| Cash & equivalents | $5.99M | $1.27M | $4.64M |
| Current assets | $6.64M | $2.25M | $4.98M |
| PP&E, net | $25,000 | $30,000 | $49,000 |
| Total assets | $7.21M | $2.86M | $5.26M |
| Current liabilities | $2.76M | $3.52M | $2.20M |
| Total liabilities | $4.61M | $6.85M | $2.25M |
| Shareholders' equity | $2.60M | -$3.99M | -$15.48M |
| Shares outstanding | 13,028 | 123.29M | 97.12M |
| Cash flow statement | |||
| Operating cash flow | -$10.82M | -$8.40M | -$4.53M |
| Capital expenditure | $9,000 | $22,000 | $12,000 |
| Free cash flow | -$10.83M | -$8.42M | -$4.54M |
| Investing cash flow | -$14,000 | -$22,000 | $573,000 |
| Financing cash flow | $15.64M | $5.10M | $522,000 |
| Depreciation & amortization | $14,000 | $25,000 | $45,000 |
| Stock-based compensation | $134,000 | $5.86M | $130,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.